Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704364 · ClinicalTrials.gov registry record · Phase 2
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2 study of Primary Sclerosing Cholangitis, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT02704364 is a Phase 2 study of Primary Sclerosing Cholangitis that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 62 participants, below the 550-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02704364, a Phase 2 study of Primary Sclerosing Cholangitis, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL NGM282
Study Locations (20)
Texas
- NGM Clinical Study Site 113 - Dallas
- NGM Clinical Study Site 117 - Dallas
- NGM Clinical Study Site 119 - Houston
- NGM Clinical Study Site 125 - Southlake
California
- NGM Clinical Study Site 118 - Sacramento
- NGM Clinical Study Site 112 - San Clemente
- NGM Clinical Study Site 127 - San Francisco
Florida
- NGM Clinical Study Site 110 - Gainesville
- NGM Clinical Study Site 124 - Lakewood Rch
- NGM Clinical Study Site 105 - Miami
Missouri
- NGM Clinical Study Site 102 - Kansas City
- NGM Clinical Study Site 107 - St Louis
Colorado
- NGM Clinical Study Site 106 - Aurora
District of Columbia
- NGM Clinical Study Site 115 - Washington D.C.
Indiana
- NGM Clinical Study Site 109 - Indianapolis
Michigan
- NGM Clinical Study Site 104 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02704364
The ClinicalTrials.gov registry entry for NCT02704364 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 550-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (89% lower). The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02704364 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02704364 about?
NCT02704364 is a clinical study titled "A Study of NGM282 in Patients With Primary Sclerosing Cholangitis". The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.
What is the current status of trial NCT02704364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2016-03. Estimated completion is 2017-06.
What conditions does trial NCT02704364 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
What interventions are being tested in trial NCT02704364?
The interventions under investigation include: Placebo (OTHER), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02704364?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02704364 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
RECRUITING · Phase 2
-
Detoxification of the Liver In PSC (Dolphin)
RECRUITING · Phase 2
-
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
ACTIVE NOT RECRUITING · Phase 2
-
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.